Cardiogeni (AQSE:CGNI) Other Current Payables: £0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni Other Current Payables?

Cardiogeni AQSE:CGNI Other Current Payables is £0.00 Mil as of . 20.

Cardiogeni's Other Current Payables for the quarter that ended in . 20 was £0.00 Mil.

Cardiogeni Other Current Payables Related Terms

Cardiogeni Other Current Payables Historical Data

* Premium members only.

The historical data trend for Cardiogeni's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni Other Current Payables Chart

Cardiogeni Annual Data
Trend
Other Current Payables

Cardiogeni Semi-Annual Data
Other Current Payables

Cardiogeni Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of £0.00 Mil mean?
Cardiogeni (AQSE:CGNI) has a Other Current Payables of £0.00 Mil as of . 20. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's Other Current Payables too high?
Cardiogeni's current Other Current Payables is £0.00 Mil.
How does Cardiogeni's Other Current Payables compare to ?
Cardiogeni's Other Current Payables of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cardiogeni and its competitors. Cardiogeni's current Other Current Payables is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current Other Current Payables of £0.00 Mil. The current Other Current Payables is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current Other Current Payables is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.